CN116615217A - 炎症性疾病和/或疼痛性疾病的预防或治疗药 - Google Patents
炎症性疾病和/或疼痛性疾病的预防或治疗药 Download PDFInfo
- Publication number
- CN116615217A CN116615217A CN202280007513.8A CN202280007513A CN116615217A CN 116615217 A CN116615217 A CN 116615217A CN 202280007513 A CN202280007513 A CN 202280007513A CN 116615217 A CN116615217 A CN 116615217A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- glutathione trisulfide
- steroidal anti
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 35
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 29
- 239000003814 drug Substances 0.000 title claims description 38
- 229940124597 therapeutic agent Drugs 0.000 title claims description 26
- 230000003449 preventive effect Effects 0.000 title abstract description 11
- 108700026078 glutathione trisulfide Proteins 0.000 claims abstract description 132
- 150000003839 salts Chemical class 0.000 claims abstract description 94
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 89
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 67
- 230000000069 prophylactic effect Effects 0.000 claims description 23
- -1 amino acid salt Chemical class 0.000 claims description 22
- 229910052783 alkali metal Inorganic materials 0.000 claims description 11
- 150000001484 arginines Chemical class 0.000 claims description 10
- 159000000000 sodium salts Chemical class 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 238000011282 treatment Methods 0.000 description 16
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 14
- 230000002265 prevention Effects 0.000 description 13
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229960000905 indomethacin Drugs 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229960003180 glutathione Drugs 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010050902 Postoperative thrombosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000004672 propanoic acids Chemical class 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003870 salicylic acids Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
通过将三硫化谷胱甘肽或其药剂学上可接受的盐与非甾体抗炎药或其药剂学上可接受的盐组合给药,对炎症性疾病和/或疼痛性疾病发挥出高的预防效果和/或治疗效果。
Description
技术领域
本发明涉及炎症性疾病和/或疼痛性疾病的预防或治疗药。
背景技术
非甾体抗炎药(Non-SteroidalAnti-InflammatoryDrugs:NSAIDs)为通过抑制作为前列腺素合成酶的环氧合酶(COX)而发挥抗炎作用、解热作用、镇痛作用、抗凝作用的药剂,被广泛用于医疗(例如专利文献1)。
三硫化谷胱甘肽(GSSSG)这样的多硫化物类在生物体内被转化为氧化型谷胱甘肽(GSSH)这样的活性硫分子。有报告称活性硫分子种可能具有强抗氧化作用、具有防止衰老等生理功能(例如非专利文献1、2)。
现有技术文献
专利文献
专利文献1:日本特表2021-500384号公报
非专利文献
非专利文献1:T.Ida,et al,.PNAS,May27,2014,111(21)7606-7611非专利文献2:T.Akaike,et al,,Nature Communications,2017,Oct27;8(1):1177
发明内容
发明所要解决的问题
本发明的目的在于提供具有高的预防效果或治疗效果的炎症性疾病和/或疼痛性疾病的预防或治疗药。
用于解决问题的方法
本发明人发现,将非甾体抗炎药与三硫化谷胱甘肽组合给药时,对炎症性疾病和/或疼痛性疾病显示出高的预防或治疗效果,从而完成了本发明。
本发明提供以下的[1]~[46]。
[1]一种含有非甾体抗炎药或其药剂学上可接受的盐的炎症性疾病和/或疼痛性疾病的预防或治疗药,其特征在于,将其与三硫化谷胱甘肽或其药剂学上可接受的盐组合给药。
[2]一种含有三硫化谷胱甘肽或其药剂学上可接受的盐的炎症性疾病和/或疼痛性疾病的预防或治疗药,其特征在于,将其与非甾体抗炎药或其药剂学上可接受的盐组合给药。
[3]根据[1]或[2]所述的预防或治疗药,其中,将三硫化谷胱甘肽或其药剂学上可接受的盐和非甾体抗炎药或其药剂学上可接受的盐同时给药或者分别给药。
[4]一种炎症性疾病和/或疼痛性疾病的预防或治疗药,其含有三硫化谷胱甘肽或其药剂学上可接受的盐和非甾体抗炎药或其药剂学上可接受的盐。
[5]根据[1]~[4]中任一项所述的预防或治疗药,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的氨基酸盐和三硫化谷胱甘肽的碱金属盐组成的组中的至少一种。
[6]根据[1]~[4]中任一项所述的预防或治疗药,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的精氨酸盐和三硫化谷胱甘肽的钠盐组成的组中的至少一种。
[7]根据[1]~[6]中任一项所述的预防或治疗药,其中,非甾体抗炎药或其药剂学上可接受的盐包含选自由水杨酸类非甾体抗炎药、丙酸类非甾体抗炎药和乙酸类非甾体抗炎药组成的组中的至少一种。
[8]一种炎症性疾病和/或疼痛性疾病的预防或治疗用试剂盒,其包含含有三硫化谷胱甘肽或其药剂学上可接受的盐的制剂和含有非甾体抗炎药或其药剂学上可接受的盐的制剂。
[9]根据[8]所述的试剂盒,其中,将含有三硫化谷胱甘肽或其药剂学上可接受的盐的制剂和含有非甾体抗炎药或其药剂学上可接受的盐的制剂同时给药或者分别给药。
[10]根据[8]或[9]所述的试剂盒,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的氨基酸盐和三硫化谷胱甘肽的碱金属盐组成的组中的至少一种。
[11]根据[8]或[9]所述的试剂盒,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的精氨酸盐和三硫化谷胱甘肽的钠盐组成的组中的至少一种。
[12]根据[8]~[11]中任一项所述的试剂盒,其中,非甾体抗炎药或其药剂学上可接受的盐包含选自由水杨酸类非甾体抗炎药、丙酸类非甾体抗炎药和乙酸类非甾体抗炎药组成的组中的至少一种。
[13]一种炎症性疾病和/或疼痛性疾病的预防或治疗方法,其中,将三硫化谷胱甘肽或其药剂学上可接受的盐和非甾体抗炎药或其药剂学上可接受的盐向需要它们的患者给药。
[14]根据[13]所述的方法,其中,将三硫化谷胱甘肽或其药剂学上可接受的盐和非甾体抗炎药或其药剂学上可接受的盐同时给药或者分别给药。
[15]根据[13]或[14]所述的方法,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的氨基酸盐和三硫化谷胱甘肽的碱金属盐组成的组中的至少一种。
[16]根据[13]或[14]所述的方法,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的精氨酸盐和三硫化谷胱甘肽的钠盐组成的组中的至少一种。
[17]根据[13]~[16]中任一项所述的方法,其中,非甾体抗炎药或其药剂学上可接受的盐包含选自由水杨酸类非甾体抗炎药、丙酸类非甾体抗炎药和乙酸类非甾体抗炎药组成的组中的至少一种。
[18]用于在炎症性疾病和/或疼痛性疾病的预防或治疗中使用的非甾体抗炎药或其药剂学上可接受的盐,其特征在于,将其与三硫化谷胱甘肽或其药剂学上可接受的盐组合给药。
[19]根据[18]所述的用于在炎症性疾病和/或疼痛性疾病的预防或治疗中使用的非甾体抗炎药或其药剂学上可接受的盐,其中,将三硫化谷胱甘肽或其药剂学上可接受的盐和非甾体抗炎药或其药剂学上可接受的盐同时给药或者分别给药。
[20]根据[18]或[19]所述的用于在炎症性疾病和/或疼痛性疾病的预防或治疗中使用的非甾体抗炎药或其药剂学上可接受的盐,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的氨基酸盐和三硫化谷胱甘肽的碱金属盐组成的组中的至少一种。
[21]根据[18]或[19]所述的用于在炎症性疾病和/或疼痛性疾病的预防或治疗中使用的非甾体抗炎药或其药剂学上可接受的盐,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的精氨酸盐和三硫化谷胱甘肽的钠盐组成的组中的至少一种。
[22]根据[18]~[21]中任一项所述的用于在炎症性疾病和/或疼痛性疾病的预防或治疗中使用的非甾体抗炎药或其药剂学上可接受的盐,其中,非甾体抗炎药或其药剂学上可接受的盐包含选自由水杨酸类非甾体抗炎药、丙酸类非甾体抗炎药和乙酸类非甾体抗炎药组成的组中的至少一种。
[23]用于在炎症性疾病和/或疼痛性疾病的预防或治疗中使用的三硫化谷胱甘肽或其药剂学上可接受的盐,其特征在于,将其与非甾体抗炎药或其药剂学上可接受的盐组合给药。
[24]根据[23]所述的用于在炎症性疾病和/或疼痛性疾病的预防或治疗中使用的三硫化谷胱甘肽或其药剂学上可接受的盐,其中,将三硫化谷胱甘肽或其药剂学上可接受的盐和非甾体抗炎药或其药剂学上可接受的盐同时给药或者分别给药。
[25]根据[23]或[24]所述的用于在炎症性疾病和/或疼痛性疾病的预防或治疗中使用的三硫化谷胱甘肽或其药剂学上可接受的盐,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的氨基酸盐和三硫化谷胱甘肽的碱金属盐组成的组中的至少一种。
[26]根据[23]或[24]所述的用于在炎症性疾病和/或疼痛性疾病的预防或治疗中使用的三硫化谷胱甘肽或其药剂学上可接受的盐,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的精氨酸盐和三硫化谷胱甘肽的钠盐组成的组中的至少一种。
[27]根据[23]~[26]中任一项所述的用于在炎症性疾病和/或疼痛性疾病的预防或治疗中使用的三硫化谷胱甘肽或其药剂学上可接受的盐,其中,非甾体抗炎药或其药剂学上可接受的盐包含选自由水杨酸类非甾体抗炎药、丙酸类非甾体抗炎药和乙酸类非甾体抗炎药组成的组中的至少一种。
[28]用于在炎症性疾病和/或疼痛性疾病的预防或治疗中使用的三硫化谷胱甘肽或其药剂学上可接受的盐与非甾体抗炎药或其药剂学上可接受的盐的组合。
[29]根据[28]所述的组合,其中,将三硫化谷胱甘肽或其药剂学上可接受的盐和非甾体抗炎药或其药剂学上可接受的盐同时给药或者分别给药。
[30]根据[28]或[29]所述的组合,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的氨基酸盐和三硫化谷胱甘肽的碱金属盐组成的组中的至少一种。
[31]根据[28]或[29]所述的组合,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的精氨酸盐和三硫化谷胱甘肽的钠盐组成的组中的至少一种。
[32]根据[28]~[31]中任一项所述的组合,其中,非甾体抗炎药或其药剂学上可接受的盐包含选自由水杨酸类非甾体抗炎药、丙酸类非甾体抗炎药和乙酸类非甾体抗炎药组成的组中的至少一种。
[33]非甾体抗炎药或其药剂学上可接受的盐在制造炎症性疾病和/或疼痛性疾病的预防或治疗药中的应用,其特征在于,将非甾体抗炎药或其药剂学上可接受的盐与三硫化谷胱甘肽或其药剂学上可接受的盐组合给药。
[34]根据[33]所述的应用,其中,将三硫化谷胱甘肽或其药剂学上可接受的盐和非甾体抗炎药或其药剂学上可接受的盐同时给药或者分别给药。
[35]根据[33]或[34]所述的应用,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的氨基酸盐和三硫化谷胱甘肽的碱金属盐组成的组中的至少一种。
[36]根据[33]或[34]所述的应用,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的精氨酸盐和三硫化谷胱甘肽的钠盐组成的组中的至少一种。
[37]根据[33]~[36]中任一项所述的应用,其中,非甾体抗炎药或其药剂学上可接受的盐包含选自由水杨酸类非甾体抗炎药、丙酸类非甾体抗炎药和乙酸类非甾体抗炎药组成的组中的至少一种。
[38]三硫化谷胱甘肽或其药剂学上可接受的盐在制造炎症性疾病和/或疼痛性疾病的预防或治疗药中的应用,其特征在于,将三硫化谷胱甘肽或其药剂学上可接受的盐与非甾体抗炎药或其药剂学上可接受的盐组合给药。
[39]根据[38]所述的应用,其中,将三硫化谷胱甘肽或其药剂学上可接受的盐和非甾体抗炎药或其药剂学上可接受的盐同时给药或者分别给药。
[40]根据[38]或[39]所述的应用,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的氨基酸盐和三硫化谷胱甘肽的碱金属盐组成的组中的至少一种。
[41]根据[38]或[39]所述的应用,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的精氨酸盐和三硫化谷胱甘肽的钠盐组成的组中的至少一种。
[42]根据[38]~[41]中任一项所述的应用,其中,非甾体抗炎药或其药剂学上可接受的盐包含选自由水杨酸类非甾体抗炎药、丙酸类非甾体抗炎药和乙酸类非甾体抗炎药组成的组中的至少一种。
[43]非甾体抗炎药或其药剂学上可接受的盐与三硫化谷胱甘肽或其药剂学上可接受的盐的组合在制造炎症性疾病和/或疼痛性疾病的预防或治疗药中的应用。
[44]根据[43]所述的应用,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的氨基酸盐和三硫化谷胱甘肽的碱金属盐组成的组中的至少一种。
[45]根据[43]所述的应用,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的精氨酸盐和三硫化谷胱甘肽的钠盐组成的组中的至少一种。
[46]根据[43]~[45]中任一项所述的应用,其中,非甾体抗炎药或其药剂学上可接受的盐包含选自由水杨酸类非甾体抗炎药、丙酸类非甾体抗炎药和乙酸类非甾体抗炎药组成的组中的至少一种。
发明效果
根据本发明,能够提供具有高的预防或治疗效果的炎症性疾病和/或疼痛性疾病的预防或治疗药。
附图说明
图1为示出在将吲哚美辛和三硫化谷胱甘肽分别单独给药的情况下以及并用给药的情况下的佐剂性关节炎模型大鼠的后肢体积的变化的图。
具体实施方式
本发明的预防或治疗药以及预防或治疗方法可对人给药或应用。
在本发明中,炎症性疾病是指以炎症为病因之一的疾病。认为本发明的预防或治疗药以及预防或治疗方法除了对炎症性疾病具有高的预防或治疗效果以外,对于以疼痛为症状之一的疼痛性疾病以及以血栓形成为病因之一的血栓性疾病也具有高的预防或治疗效果。作为包括炎症性疾病的这些疾病,可以列举例如:系统性红斑狼疮、硬皮病、特应性皮炎、接触性皮炎、银屑病、类风湿关节炎、变形性关节炎、间质性肺炎、支气管哮喘、上呼吸道感染、扁桃体炎、慢性阻塞性肺疾病、肺动脉高压、溃疡性结肠炎、克罗恩病等炎症性肠病(IBD)、神经损伤、脊髓损伤、椎管狭窄症、脑卒中(脑梗塞、脑出血后遗症)、肌萎缩侧索硬化、慢性炎性脱髓鞘性多发性神经炎、多发性硬化、帕金森病、阿尔茨海默病、血管性痴呆等痴呆症、精神分裂症、器官移植时的排斥反应、急性肾损伤、糖尿病肾衰竭、狼疮性肾炎、肾盂肾炎、IgA肾病、慢性肾病、神经病理性疼痛、骨质疏松症引起的疼痛、癌症引起的疼痛、外科手术后和外伤引起的疼痛、抗癌剂给药引起的疼痛、带状疱疹引起的疼痛、牙痛、偏头痛、肌痛、腰痛、关节痛、生理痛、痛经、烧伤、短暂性缺血性发作、心肌梗塞、心房颤动、纤维肌痛、血管内皮炎、川崎病、病毒感染后遗症、安装人工心脏瓣膜引起的血栓症、手术后的血栓症、结肠癌、直肠癌、食道癌等与前列腺素相关的癌等。
在本发明中,作为药剂学上可接受的盐,可以列举例如:与盐酸、氢溴酸、硫酸、硝酸、磷酸等无机酸的盐;与乙酸、琥珀酸、富马酸、马来酸、酒石酸、柠檬酸、乳酸、硬脂酸、苯甲酸、甲磺酸、乙磺酸、对甲苯磺酸等有机酸的盐;与钠、钾等碱金属的盐;与钙、镁等碱土金属的盐;铵盐;与精氨酸等氨基酸的盐等。
作为非甾体类抗炎药(NSAIDs),可以列举例如:乙酰水杨酸等水杨酸类;布洛芬、洛索洛芬、萘普生、酮洛芬、氟比洛芬等丙酸类;吲哚美辛、双氯芬酸等乙酸类;塞来昔布、罗非昔布等昔布类;对乙酰氨基酚、甲芬那酸、托芬那酸等苯胺类等NSAIDs。
三硫化谷胱甘肽(GSSSG)能够提高生物体内的谷胱甘肽水平,由于谷胱甘肽具有强抗氧化作用,因此生物体内的谷胱甘肽水平升高时,能够有效地保护细胞免受过氧化物、活性氧的影响。
在本发明中,“组合给药”或“并用”是指组合使用有效成分,包括(1)作为包含NSAIDs和GSSSG的单一制剂给药的方式以及(2)NSAIDs和GSSSG分别作为不同的制剂同时或者有时间差地分别给药的方式。在(2)的情况下,可以先给药NSAIDs,也可以先给药GSSSG。另外,在(2)的情况下,可以为以下方式中的任意一种方式:(i)将NSAIDs和GSSSG分别制成制剂,通过同一给药途径同时给药的方式;(ii)将NSAIDs和GSSSG分别制成制剂,通过同一给药途径有时间差地分别给药的方式;(iii)将NSAIDs和GSSSG分别制成制剂,通过不同的给药途径(从同一患者的不同部位给药)同时给药的方式;(iv)将NSAIDs和GSSSG分别制成制剂,通过不同的给药途径有时间差地分别给药的方式。需要说明的是,在(i)的情况下,可以在即将给药之前混合两种药剂。
换言之,本发明中的“组合给药”或“并用”也可以说是在患者体内表现出任意一种药剂的作用/效果(抗炎作用、镇痛作用、抗凝作用等)的状态下给药另一种药剂的使用方式。即,在本发明中,优选以NSAIDs和GSSSG同时存在于患者体内、例如血液中的方式给药的方式,优选对患者在给药一种药剂后24小时内给药另一种药剂的方式。
NSAIDs的给药量优选为每1kg体重1天0.1~50mg(0.1~50mg/kg/天),更优选为0.5~20mg/kg/天,进一步优选为1~10mg/kg/天。
GSSSG的给药量优选为每1kg体重1天0.5~1000mg(0.5~1000mg/kg/天),更优选为1~400mg/kg/天,进一步优选为2~200mg/kg/天。
优选NSAIDs的给药量为0.1~50mg/kg/天且GSSSG的给药量为0.5~1000mg/kg/天,更优选NSAIDs的给药量为0.5~20mg/kg/天且GSSSG的给药量为1~400mg/kg/天,进一步优选NSAIDs的给药量为1~10mg/kg/天且GSSSG的给药量为2~200mg/kg/天。NSAIDs和GSSSG的给药量在该范围内时,认为对炎症性疾病和/或疼痛性疾病发挥出更高的预防效果,并且显示出更高的治疗效果。此外,还可期待进一步降低副作用的效果。
NSAIDs和GSSSG的给药次数可以设定为1天1次~6次或1天1次~4次。如果是这样的给药次数,则能够减轻患者的服药负担,提高服药依从性。其结果是,能够期待本发明的预防或治疗药所发挥出的抗炎症等效果以及副作用减轻效果进一步提高。在中止药剂的给药的情况下,可以分阶段地减少药剂的用量。例如,可以列举在一种药剂的停药期间给药另一种药剂的方法。
本发明的炎症性疾病和/或疼痛性疾病的预防或治疗药可以以片剂、颗粒剂、细粒剂、粉剂、胶囊剂等固体制剂或者液剂、凝胶剂、糖浆剂等形态口服给药。另外,本发明的炎症性疾病和/或疼痛性疾病的预防或治疗药可以以注射剂、栓剂、软膏剂、泥敷剂、喷雾剂等形态非口服地给药。这些剂型可以按照公知的方法制剂化。
本发明的炎症性疾病和/或疼痛性疾病的预防或治疗药可以为将第一成分和第二成分中的任意一种或两种与水、乙醇、生理盐水、液体石蜡等混合而得到的物质。
实施例
以下列举实施例对本发明更详细地进行说明,但本发明不限于此。
<在大鼠佐剂性关节炎模型中的并用所产生的协同效果>
用电子天平称量必要量的GSSSG和吲哚美辛,使用研钵分别充分磨碎,加入溶剂(0.5%的甲基纤维素(MC)悬浮液),分别悬浮。以GSSSG单独的给药液为21.2mg/mL(无水换算为20mg/mL)、吲哚美辛单独的给药液为0.06mg/ml或0.6mg/mL的浓度的方式制作。并用给药液通过向将GSSSG以42.4mg/mL(无水换算为40mg/mL)制备而成的悬浮液中混合等量的0.12mg/ml、1.2mg/mL吲哚美辛悬浮液来制作。给药液一次性制备2周的量,在给药之前在冷藏、遮光条件下保存。
利用研钵将适量的用作佐剂的结核死菌(M.Tuberculosis H37Ra;BD)磨碎,加入液体石蜡,制备成5mg/mL。实验动物使用6周龄的雄性LEW大鼠。到货时实施一般状态观察和体重测定,确认有无异常。驯化饲养期为7天,每天观察1次一般状态。在驯化期结束日测定左后肢体积和体重,确认体重和一般状态无异常后供于试验。
在驯化期结束日,在异氟醚吸入麻醉下,使制备的佐剂50μl对大鼠的右后肢跖皮下致敏。在佐剂致敏后第9天按照下述表1进行分组。在分组中,以左后肢体积和体重均等的方式分为6组(n=5)。
[表1]
将吲哚美辛单独的给药液、GSSSG单独的给药液和并用给药液的给药设定为强制口服给药,从分组日开始14天内以5mL/kg的容量实施。需要说明的是,给药量的计算基于最近的体重计算。使用大鼠后肢足跖浮肿体积测定装置(TK-101P;株式会社夏目制作所)在驯化期结束日、分组日以及分组日以后每周2次测定左后肢(非致敏足)的体积。测定以5次/只/天来实施,体积为除去最高值和最低值后的3次的平均值。将结果示于表2和图1中。
如表2和图1所示,在GSSSG单独给药组中没有观察到抗炎效果,但是在GSSSG与吲哚美辛(0.3mg/kg)的并用给药组中观察到了抗炎效果的协同效果。另外认为,伴随着这样高的抗炎作用的表现,由炎症引起的疼痛的程度也得到改善。
[表2]
Claims (7)
1.一种含有非甾体抗炎药或其药剂学上可接受的盐的炎症性疾病和/或疼痛性疾病的预防或治疗药,其特征在于,将其与三硫化谷胱甘肽或其药剂学上可接受的盐组合给药。
2.一种含有三硫化谷胱甘肽或其药剂学上可接受的盐的炎症性疾病和/或疼痛性疾病的预防或治疗药,其特征在于,将其与非甾体抗炎药或其药剂学上可接受的盐组合给药。
3.根据权利要求1或2所述的预防或治疗药,其中,将三硫化谷胱甘肽或其药剂学上可接受的盐和非甾体抗炎药或其药剂学上可接受的盐同时给药或者分别给药。
4.一种炎症性疾病和/或疼痛性疾病的预防或治疗药,其含有三硫化谷胱甘肽或其药剂学上可接受的盐和非甾体抗炎药或其药剂学上可接受的盐。
5.根据权利要求1~4中任一项所述的预防或治疗药,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的氨基酸盐和三硫化谷胱甘肽的碱金属盐组成的组中的至少一种。
6.根据权利要求1~4中任一项所述的预防或治疗药,其中,三硫化谷胱甘肽或其药剂学上可接受的盐包含选自由三硫化谷胱甘肽、三硫化谷胱甘肽的精氨酸盐和三硫化谷胱甘肽的钠盐组成的组中的至少一种。
7.根据权利要求1~6中任一项所述的预防或治疗药,其中,非甾体抗炎药或其药剂学上可接受的盐包含选自由水杨酸类非甾体抗炎药、丙酸类非甾体抗炎药和乙酸类非甾体抗炎药组成的组中的至少一种。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-018177 | 2021-02-08 | ||
JP2021018177 | 2021-02-08 | ||
PCT/JP2022/004692 WO2022168975A1 (ja) | 2021-02-08 | 2022-02-07 | 炎症性疾患及び/又は疼痛性疾患の予防又は治療薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116615217A true CN116615217A (zh) | 2023-08-18 |
Family
ID=82741605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280007513.8A Pending CN116615217A (zh) | 2021-02-08 | 2022-02-07 | 炎症性疾病和/或疼痛性疾病的预防或治疗药 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240082194A1 (zh) |
EP (1) | EP4272759A1 (zh) |
JP (1) | JPWO2022168975A1 (zh) |
CN (1) | CN116615217A (zh) |
WO (1) | WO2022168975A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024048479A1 (ja) * | 2022-08-30 | 2024-03-07 | 国立大学法人東北大学 | 虚血再灌流傷害抑制 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001524087A (ja) * | 1997-04-18 | 2001-11-27 | クリンゲ ファーマ ジーエムビーエイチ | システイニル誘導体を含有する安定化された薬剤 |
US10420736B2 (en) * | 2015-09-30 | 2019-09-24 | Tohoku University | Antioxidizing intraocular perfusion solution |
CN111565708B (zh) | 2017-10-26 | 2023-07-25 | 浙江越甲药业有限公司 | 一种稳定的含有非甾体抗炎药衍生物的药物组合物 |
-
2022
- 2022-02-07 CN CN202280007513.8A patent/CN116615217A/zh active Pending
- 2022-02-07 US US18/263,196 patent/US20240082194A1/en active Pending
- 2022-02-07 WO PCT/JP2022/004692 patent/WO2022168975A1/ja active Application Filing
- 2022-02-07 EP EP22749846.6A patent/EP4272759A1/en active Pending
- 2022-02-07 JP JP2022579642A patent/JPWO2022168975A1/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240082194A1 (en) | 2024-03-14 |
WO2022168975A1 (ja) | 2022-08-11 |
JPWO2022168975A1 (zh) | 2022-08-11 |
EP4272759A1 (en) | 2023-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190144436A1 (en) | Administration regime for nitrocatechols | |
KR101709904B1 (ko) | Dopa 데카르복실라제 억제제의 연속투여용 조성물 | |
CA2824317C (en) | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia | |
JP2023096079A (ja) | 化合物の製剤およびそれらの使用 | |
KR20060123482A (ko) | 신장 기능을 개선하기 위한 트레프로스티닐의 용도 | |
AU2007341218B2 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
CN116615217A (zh) | 炎症性疾病和/或疼痛性疾病的预防或治疗药 | |
CN112469415A (zh) | 用于预防或治疗非酒精性脂肪性肝炎的药物组合物 | |
PT1814517E (pt) | Formulação parentérica líquida não aquosa de aceclofenac | |
TWI606826B (zh) | 艾拉莫德或其鹽之用途 | |
JP6173352B2 (ja) | 筋萎縮性側索硬化症の治療方法 | |
US20240122957A1 (en) | Use of nicotinamide mononucleotide (nmn) for the prevention and/or treatment of rheumatoid arthritis, and corresponding compositions | |
EP3851104A1 (en) | Synergic pharmaceutical combination of a selective inhibitor of cyclooxygenase-2 and an anthraquinone derivative | |
JP2019529501A (ja) | 可逆的に保護された、チオレート化求電子性脂肪酸としてのプロドラッグ | |
JPWO2019234240A5 (zh) | ||
US20200022936A1 (en) | Combinations of diclofenac, h2 receptor antagonists and alkali metal bicarbonates for the treatment of pain and inflammation | |
CA2684938A1 (en) | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions | |
JP7418502B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用 | |
Liu et al. | Enhanced water-soluble derivative of PC407 as a novel potential COX-2 inhibitor injectable formulation | |
JP6935930B2 (ja) | 生薬成分を含む肺高血圧症の予防又は治療剤 | |
TW202128200A (zh) | 誘導或增強經法尼醇x受體(fxr)介導之轉錄反應的方法 | |
CA2880399C (en) | Use of bimatoprost free acid administered to the skin to reduce adipose tissue | |
JP6192405B2 (ja) | ロキソプロフェン含有経口剤組成物 | |
CN115605455A (zh) | 酮洛芬、赖氨酸和加巴喷丁的共晶、药物组合物及其医药用途 | |
JP2011157298A (ja) | 胃潰瘍治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |